Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1

Conditions

Gastrointestinal Stromal Tumors 71Sarcoma 12Brain Neoplasms 10Gliosarcoma 9Glioblastoma 9Neoplasm Metastasis 6Glioma 6Dermatofibrosarcoma 6Oligodendroglioma 5Central Nervous System Neoplasms 5Astrocytoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Fibrosarcoma 4Chordoma 4Sarcoma, Synovial 3Osteosarcoma 3Neurofibrosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Liposarcoma 3Hemangiosarcoma 3Glioma, Subependymal 3Digestive System Neoplasms 3Desmoid Tumors 3Sarcoma, Endometrial Stromal 2Recurrence 2Primary Myelofibrosis 2Piebaldism 2Multiple Myeloma 2Meningioma 2

Interventions

ripretinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Imatinib Mesylate × Sarcoma × Clear all
NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Novartis

Phase 2 Completed
38 enrolled
MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡